ADARx Pharmaceuticals, Inc. (ADRX) 8-K Filings: Every Material Event, Explained

ADRX 8-K filings, explained

Every material Form 8-K ADARx Pharmaceuticals, Inc. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs on record1since Sep 28, 2026

Latest filingSep 28, 2026financing

High impact (4-5)1of 1 brief

ToneNeutral1

Sep 28, 4:01 PM ET

ADARx closes IPO at $17.00 per share, raising $446.3 million; AbbVie buys $89.3 million

Neutral financing Written later 3.02 5.03 8.01

ADARx Pharmaceuticals closed its initial public offering on September 28, 2026, selling 26,250,000 shares at $17.00 each for approximately $446.3 million in gross proceeds. AbbVie bought 5,255,542 shares in a concurrent private placement for approximately $89.3 million in gross proceeds, leaving it with about 4.9% of outstanding common stock after the closings. The company also adopted an amended and restated certificate of incorporation and bylaws in connection with the IPO.

IPO closed September 28, 2026: 26,250,000 shares at $17.00 per share, approximately $446.3 million in gross proceeds.
AbbVie bought 5,255,542 shares in a private placement at the IPO price, approximately $89.3 million in gross proceeds, owning about 4.9% after closing.
Placement agent fee was 2.0% of the private placement purchase price; J.P. Morgan, Morgan Stanley, TD Securities, UBS and LifeSci Capital acted as agents.
Amended and restated certificate of incorporation and bylaws took effect September 28, 2026.

Read the filing on SEC.gov ↗